Euronext

AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

Retrieved on: 
Friday, March 1, 2024
Q&A, LIVE, Euronext

AB SCIENCE WILL HOST A LIVE WEBCAST ON MONDAY MARCH 4, 2024 FROM 6.30PM TO 7.30PM CET

Key Points: 
  • AB SCIENCE WILL HOST A LIVE WEBCAST ON MONDAY MARCH 4, 2024 FROM 6.30PM TO 7.30PM CET
    AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET.
  • The agenda of this live webcast will be to provide status and perspective on the following topics:
    The presentation will be followed by a Q&A session.

ONWARD® Medical Awarded 10th Breakthrough Device Designation for Brain-Computer Interface (BCI) from US FDA

Retrieved on: 
Thursday, February 29, 2024
Nature, SCI, Artificial intelligence, Paralysis, BCI, FDA, ARC, Food, Euronext, BDD, Learning, Communication, History, Walking, Spinal cord, Movement, Area studies, Brain, Medical device

This is the tenth FDA BDD awarded to ONWARD Medical.

Key Points: 
  • This is the tenth FDA BDD awarded to ONWARD Medical.
  • The designation is reserved for novel, cutting-edge therapies addressing an unmet need and provides many potential regulatory and reimbursement advantages.
  • This latest award gives ONWARD Medical priority FDA review, the opportunity to interact with FDA experts throughout the pre-market regulatory review phase, and the potential to seek additional reimbursement for its ARC-BCI System.
  • “Brain-computer interface technology unlocks the transformative potential to enhance ARC-IM with thought-driven control of movement after paralysis,” said ONWARD Medical CEO Dave Marver.

Okeanis Eco Tankers Corp. – Key Information relating to 4Q23 capital distribution

Retrieved on: 
Thursday, February 29, 2024
Dividend, CSDR, ECO, Euronext

ATHENS, Greece, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. (the “OET” or the “Company”) (NYSE: ECO / OSE: OET), will pay a dividend on its common shares, which is classified as a return of capital (the “Dividend”).

Key Points: 
  • ATHENS, Greece, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. (the “OET” or the “Company”) (NYSE: ECO / OSE: OET), will pay a dividend on its common shares, which is classified as a return of capital (the “Dividend”).
  • Key information relating to the Dividend to be paid by the Company for the fourth quarter of 2023 can be found below:
    Payment date: March 22, 2024.
  • Due to the implementation of Central Securities Depository Regulation (CSDR) in Norway, the Dividend payable on common shares that are registered in the Euronext VPS is expected to be distributed to Euronext VPS shareholders on or about March 27, 2024.

Okeanis Eco Tankers Corp. – Unaudited Condensed Financial Statements for the Fourth Quarter and Twelve Month Period of 2023

Retrieved on: 
Thursday, February 29, 2024
NOK, Holocene, Suezmax, TCE, CSDR, ECO, Sale, Calendar, Exercise, OET, Euronext, Webcast, Bank statement, CMB, VLCC

ATHENS, Greece, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. (“OET” or “Company”) (NYSE:ECO / OSE:OET) today reported unaudited condensed financial statements for the fourth quarter and twelve month period of 2023, which are attached to this press release.

Key Points: 
  • ATHENS, Greece, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. (“OET” or “Company”) (NYSE:ECO / OSE:OET) today reported unaudited condensed financial statements for the fourth quarter and twelve month period of 2023, which are attached to this press release.
  • Adjusted profit and Adjusted earnings per share (non-IFRS measures*) for the period of $20.4 million or $0.63 per basic & diluted share.
  • Fleetwide daily TCE rate of $45,400 per operating day; VLCC and Suezmax TCE rates of $45,200 and $45,600 per operating day, respectively.
  • OET will be hosting a conference call and webcast at 13:30 CET on Thursday February 29, 2024, to discuss the Q4 2023 results.

Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Retrieved on: 
Thursday, February 29, 2024
Obstructive sleep apnea, Euronext, Conference, OSA, Medtech, Mont-Saint-Guibert

Mont-Saint-Guibert, Belgium – February 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference, which takes place March 12 – 13, 2024.

Key Points: 
  • Mont-Saint-Guibert, Belgium – February 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference, which takes place March 12 – 13, 2024.
  • Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate presentation on Tuesday, March 12, 2024, at 10:40am ET.
  • A webcast of the presentation will be available in the Events section of Nyxoah’s Investor Relations website.
  • Nyxoah’s Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

Retrieved on: 
Thursday, February 29, 2024
Q&A, LIVE, Euronext, Broadcasting

AB SCIENCE WILL HOST A LIVE WEBCAST ON MONDAY MARCH 4, 2024 FROM 6.30PM TO 7.30PM CET

Key Points: 
  • AB SCIENCE WILL HOST A LIVE WEBCAST ON MONDAY MARCH 4, 2024 FROM 6.30PM TO 7.30PM CET
    AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET.
  • The agenda of this live webcast will be to provide status and perspective on the following topics:
    The presentation will be followed by a Q&A session.
  • Login details for this live webcast will be provided later.

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Retrieved on: 
Thursday, February 29, 2024
DGF, Neonatal Fc receptor, ALS, Congenital myasthenic syndrome, CMS, CIDP, MMN, Alfa Romeo, IIP, IL-6, FDA, Inflammation, MHLW, PDUFA, Euronext, Neurology, MuSK protein, Kidney, ARDA, Health care, C2, GMG, Ministry of Health, Dermatomyositis, Patient, Efgartigimod alfa, MHRA, Medicine, Multifocal motor neuropathy, Immune system, Pharmaceutical industry

“argenx reached thousands of new patients and their families in 2023 by delivering on our commitment to make VYVGART available to the global MG community,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx reached thousands of new patients and their families in 2023 by delivering on our commitment to make VYVGART available to the global MG community,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • Clinically, we generated significant data through multiple study readouts, achieving key milestones for both the CIDP and MMN patient communities and importantly advancing our second molecule, empasiprubart.
  • Looking forward to 2024, we will act with a continued sense of purpose to expand our patient reach.
  • In addition, argenx is evaluating ARGX-119, a muscle-specific kinase (MuSK) agonist in both congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS).

Crossject obtains a financing up to €12 million, in two tranches

Retrieved on: 
Tuesday, February 27, 2024
Person, FDA, Convertible, Observation, Euronext, AMF, Element, Tranche, Market value, Mass meeting, Market, Prospectus, Security (finance)

Subject to the Company's consent, he also has the right to request the deferral of payment of an early amortization installment.

Key Points: 
  • Subject to the Company's consent, he also has the right to request the deferral of payment of an early amortization installment.
  • Crossject will publish the number of new stocks issued under the terms of the convertible bonds on its website regularly.
  • The aim of the proceeds is to enable Crossject to ramp up industrial and commercial development of its ZENEO technology.
  • The Company is also confident in its ability to find, if needed, the necessary financing to continue its development.

argenx to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, February 26, 2024
Euronext, Conference

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in March:

Key Points: 
  • Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in March:
    TD Cowen 44th Annual Health Care Conference.
  • Fireside chat on Monday, March 4, 2024 at 11:10 a.m.
  • ET in Boston, MA.

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

Retrieved on: 
Thursday, February 22, 2024
NSCLC, NCT, Galapagos NV, Euronext, Safety, Pharmacokinetics, Medicine, Patient, Acceleration, Proteome, Clinical trial, Science, Medication, Pharmaceutical industry

BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced the close of an oversubscribed $80 million Series C financing. The financing was co-led by Deerfield Management Company and Droia Ventures, with significant participation from Galapagos NV (Euronext & NASDAQ: GLPG) as a strategic investor, and contributions from new and existing investors including DCVC Bio, MPM Capital, and RA Capital Management. This Series C financing brings the total capital raised since Frontier’s founding to $235.5 million.

Key Points: 
  • This Series C financing brings the total capital raised since Frontier’s founding to $235.5 million.
  • “Frontier Medicines is a leading chemoproteomics company with a unique technology platform and a pipeline of potential best-in-class assets that fit with Galapagos’ precision oncology R&D approach.
  • The participation in Frontier Medicines' Series C round aligns with our innovation acceleration strategy to bring transformational medicines to patients around the world.”
    Financing proceeds will support the advancement of multiple wholly-owned pipeline programs into clinical studies, including FMC-376.
  • “Today we mark the first participant dosed with a therapeutic candidate born from the Frontier™ Platform, alongside a financing that affirms continued strong investor support.